New Melanoma Therapy to Debut at ESMO Congress 2026
A new autologous therapy for advanced metastatic melanoma will reveal early clinical results in late October.
Updated on Oct. 13, 2026 in Cancer
Live Poll
Should companies present preliminary clinical data for new cancer therapies before final study results exist?
Novastra Therapeutics will present initial clinical data for its OAP-101 candidate on October 24, 2026, at the ESMO Congress in Madrid. The therapy is currently in a Phase 1 study for patients with advanced metastatic melanoma who have not responded to anti-PD-1 checkpoint inhibition.
Why it matters
Researchers are investigating the OAP-101 approach to address the resistance that cold solid tumors often show to current immunotherapy treatments. This development marks a new attempt to improve outcomes for patients who have exhausted standard checkpoint inhibition options.
This preliminary Phase 1 clinical study evaluates the OAP-101 autologous candidate in patients with advanced metastatic melanoma who are refractory to anti-PD-1 checkpoint inhibition. Detailed results from the trial will be presented in poster 2000P at the upcoming congress.
The players
Novastra Therapeutics
A clinical-stage biotechnology company focused on developing new cancer immunotherapies.
Junling Guo
The Chief Executive Officer of Novastra Therapeutics.
The details
The OAP-101 therapy uses a supramolecular nanocloak to encapsulate tumor-cell antigens for immune system presentation. By combining antigen delivery with the activation of the innate cGAS-STING pathway, the system is engineered to prime the immune system against cold solid tumors. This dual-action approach aims to bypass the resistance mechanisms that frequently limit the effectiveness of traditional checkpoint inhibitors in melanoma patients.
Timeline
October 19, 2026: Full abstract available at 12:05 a.m. CEST.
October 23-27, 2026: The ESMO Congress 2026 occurs in Madrid, Spain.
October 24, 2026: Initial clinical data for OAP-101 will be presented between 12:00 and 12:45 CEST.
Health Landscape
The clinical investigation of OAP-101 is part of a broader shift in oncology toward overcoming immunotherapy resistance in cold solid tumors. This research aligns with the current push to use novel delivery systems to stimulate immune pathways like cGAS-STING where standard checkpoint inhibition fails.
Patients with advanced metastatic melanoma currently managing treatment resistance should track this upcoming data release as it may inform future clinical trial options. If you are currently in treatment for melanoma, this is a topic to keep on your radar for an upcoming conversation with your oncologist.
The takeaway
The upcoming data presentation highlights new methods for potentially re-activating the immune response against metastatic melanoma. Patients or their caregivers may want to monitor reports from the ESMO Congress 2026 to stay informed about how these experimental pathways may eventually fit into clinical practice.
What happens next
The full abstract for the study will be available on October 19, 2026, followed by the formal data presentation on October 24, 2026.
Further reading
For more information on the latest approaches to managing aggressive skin malignancies, visit our Cancer section.
Live Poll
Should companies present preliminary clinical data for new cancer therapies before final study results exist?
